List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4865995/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study. BMJ, The, 2009, 338, b2255-b2255.	6.0	404
2	Comparative Effectiveness and Safety of Bariatric Procedures for Weight Loss. Annals of Internal Medicine, 2018, 169, 741.	3.9	210
3	Comparative Risk for Angioedema Associated With the Use of Drugs That Target the Renin-Angiotensin-Aldosterone System. Archives of Internal Medicine, 2012, 172, 1582.	3.8	178
4	Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiology and Drug Safety, 2016, 25, 2-10.	1.9	164
5	The U.S. Food and Drug Administration's Miniâ€Sentinel program: status and direction. Pharmacoepidemiology and Drug Safety, 2012, 21, 1-8.	1.9	155
6	Comparing the 5-Year Diabetes Outcomes of Sleeve Gastrectomy and Gastric Bypass. JAMA Surgery, 2020, 155, e200087.	4.3	138
7	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. Pharmacoepidemiology and Drug Safety, 2017, 26, 1018-1032.	1.9	126
8	Validity of health plan and birth certificate data for pregnancy research. Pharmacoepidemiology and Drug Safety, 2013, 22, 7-15.	1.9	114
9	Data Quality Assessment for Comparative Effectiveness Research in Distributed Data Networks. Medical Care, 2013, 51, S22-S29.	2.4	112
10	Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001–2007: a population-based study of 585,615 deliveries. Archives of Women's Mental Health, 2013, 16, 149-157.	2.6	107
11	Potential Bias of Instrumental Variable Analyses for Observational Comparative Effectiveness Research. Annals of Internal Medicine, 2014, 161, 131.	3.9	103
12	Network meta-analysis incorporating randomized controlled trials and non-randomized comparative cohort studies for assessing the safety and effectiveness of medical treatments: challenges and opportunities. Systematic Reviews, 2015, 4, 147.	5.3	99
13	Coronary Heart Disease in Postmenopausal Recipients of Estrogen Plus Progestin Therapy: Does the Increased Risk Ever Disappear?. Annals of Internal Medicine, 2010, 152, 211.	3.9	97
14	Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs. Annals of Internal Medicine, 2016, 164, 705.	3.9	91
15	Selective Serotonin Reuptake Inhibitor Use and Risk of Gestational Hypertension. American Journal of Psychiatry, 2009, 166, 320-328.	7.2	89
16	Causal Inference from Longitudinal Studies with Baseline Randomization. International Journal of Biostatistics, 2008, 4, Article 22.	0.7	88
17	Validation of an algorithm to estimate gestational age in electronic health plan databases. Pharmacoepidemiology and Drug Safety, 2013, 22, 524-532.	1.9	87
18	Pregnancy-Associated Cancer: A U.S. Population-Based Study. Journal of Women's Health, 2019, 28, 250-257.	3.3	87

#	Article	IF	CITATIONS
19	Interventions and Operations 5 Years After Bariatric Surgery in a Cohort From the US National Patient-Centered Clinical Research Network Bariatric Study. JAMA Surgery, 2020, 155, 194.	4.3	82
20	Statins and fracture risk. A systematic review. Pharmacoepidemiology and Drug Safety, 2007, 16, 627-640.	1.9	75
21	Confounding adjustment via a semiâ€automated highâ€dimensional propensity score algorithm: an application to electronic medical records. Pharmacoepidemiology and Drug Safety, 2011, 20, 849-857.	1.9	75
22	Validation of acute myocardial infarction in the Food and Drug Administration's Mini‣entinel program. Pharmacoepidemiology and Drug Safety, 2013, 22, 40-54.	1.9	71
23	Comparative effectiveness of bariatric procedures among adolescents: the PCORnet bariatric study. Surgery for Obesity and Related Diseases, 2018, 14, 1374-1386.	1.2	71
24	Use of realâ€world evidence in regulatory decisions for rare diseases in the United States—Current status and future directions. Pharmacoepidemiology and Drug Safety, 2020, 29, 1213-1218.	1.9	71
25	Antidepressant Use During Pregnancy and the Risk of Preterm Delivery and Fetal Growth Restriction. Journal of Clinical Psychopharmacology, 2009, 29, 555-560.	1.4	70
26	Chronic opioid use emerging after bariatric surgery. Pharmacoepidemiology and Drug Safety, 2014, 23, 1247-1257.	1.9	69
27	Trends in the Use of Antiepileptic Drugs among Pregnant Women in the US, 2001–2007: A Medication Exposure in Pregnancy Risk Evaluation Program Study. Paediatric and Perinatal Epidemiology, 2012, 26, 578-588.	1.7	68
28	Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Medical Care, 2017, 55, 1046-1051.	2.4	67
29	A critical review of methods to evaluate the impact of FDA regulatory actions. Pharmacoepidemiology and Drug Safety, 2013, 22, 986-994.	1.9	66
30	Sensitivity and Specificity of Computerized Algorithms to Classify Gestational Periods in the Absence of Information on Date of Conception. American Journal of Epidemiology, 2007, 167, 633-640.	3.4	63
31	Comparative-Effectiveness Research in Distributed Health Data Networks. Clinical Pharmacology and Therapeutics, 2011, 90, 883-887.	4.7	62
32	Early Antibiotic Exposure and Weight Outcomes in Young Children. Pediatrics, 2018, 142, .	2.1	59
33	Estimating Absolute Risks in the Presence of Nonadherence. Epidemiology, 2010, 21, 528-539.	2.7	57
34	Medication Exposure in Pregnancy Risk Evaluation Program. Maternal and Child Health Journal, 2012, 16, 1349-1354.	1.5	57
35	Using Machine Learning to Identify Health Outcomes from Electronic Health Record Data. Current Epidemiology Reports, 2018, 5, 331-342.	2.4	56
36	Confounding Adjustment in Comparative Effectiveness Research Conducted Within Distributed Research Networks. Medical Care, 2013, 51, S4-S10.	2.4	55

#	Article	IF	CITATIONS
37	Association of Infections and Use of Fluoroquinolones With the Risk of Aortic Aneurysm or Aortic Dissection. JAMA Internal Medicine, 2020, 180, 1587.	5.1	51
38	Cancer Risk Associated with Insulin Glargine among Adult Type 2 Diabetes Patients – A Nationwide Cohort Study. PLoS ONE, 2011, 6, e21368.	2.5	49
39	Antiemetic use among pregnant women in the United States: the escalating use of ondansetron. Pharmacoepidemiology and Drug Safety, 2017, 26, 592-596.	1.9	47
40	Design considerations in an active medical product safety monitoring system. Pharmacoepidemiology and Drug Safety, 2012, 21, 32-40.	1.9	46
41	Validity of diagnostic codes to identify cases of severe acute liver injury in the U.S. Food and Drug Administration's Mini‧entinel Distributed Database. Pharmacoepidemiology and Drug Safety, 2013, 22, 861-872.	1.9	46
42	Medication Exposure in Pregnancy Risk Evaluation Program: The Prevalence of Asthma Medication Use During Pregnancy. Maternal and Child Health Journal, 2013, 17, 1611-1621.	1.5	44
43	Trends in 30-day readmission rates after COPD hospitalization, 2006–2012. Respiratory Medicine, 2017, 130, 92-97.	2.9	44
44	Early impact of the ICDâ€10â€CM transition on selected health outcomes in 13 electronic health care databases in the United States. Pharmacoepidemiology and Drug Safety, 2018, 27, 839-847.	1.9	44
45	Use of selective serotonin reuptake inhibitors (SSRIs) in women delivering liveborn infants and other women of child-bearing age within the U.S. Food and Drug Administration's Mini-Sentinel program. Archives of Women's Mental Health, 2016, 19, 969-977.	2.6	42
46	Antibiotics and oral contraceptive failure — a case-crossover study. Contraception, 2011, 83, 418-425.	1.5	37
47	Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice. Annals of Internal Medicine, 2017, 167, 845.	3.9	37
48	The National Patient-Centered Clinical Research Network (PCORnet) Bariatric Study Cohort: Rationale, Methods, and Baseline Characteristics. JMIR Research Protocols, 2017, 6, e222.	1.0	37
49	Stakeholders' views on data sharing in multicenter studies. Journal of Comparative Effectiveness Research, 2017, 6, 537-547.	1.4	36
50	A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent. Pharmacoepidemiology and Drug Safety, 2012, 21, 282-290.	1.9	34
51	Is Size the Next Big Thing in Epidemiology?. Epidemiology, 2013, 24, 349-351.	2.7	34
52	Use of antidepressants and risk of lung cancer. Cancer Causes and Control, 2007, 18, 1055-1064.	1.8	33
53	Design for validation of acute myocardial infarction cases in Mini‣entinel. Pharmacoepidemiology and Drug Safety, 2012, 21, 274-281.	1.9	33
54	Successful Comparison of US Food and Drug Administration Sentinel Analysis Tools to Traditional Approaches in Quantifying a Known Drugâ€Adverse Event Association. Clinical Pharmacology and Therapeutics, 2016, 100, 558-564.	4.7	33

#	Article	IF	CITATIONS
55	Multivariable confounding adjustment in distributed data networks without sharing of patientâ€level data. Pharmacoepidemiology and Drug Safety, 2013, 22, 1171-1177.	1.9	32
56	Sentinel Modular Program for Propensity Score–Matched Cohort Analyses. Epidemiology, 2017, 28, 838-846.	2.7	32
57	Surveillance of Medication Use During Pregnancy in the Mini-Sentinel Program. Maternal and Child Health Journal, 2016, 20, 895-903.	1.5	31
58	Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?. Pharmacoepidemiology and Drug Safety, 2012, 21, 524-534.	1.9	30
59	Administrative Claims Data Versus Augmented Pregnancy Data for the Study of Pharmaceutical Treatments in Pregnancy. Current Epidemiology Reports, 2017, 4, 106-116.	2.4	30
60	Inverse probability weighted Cox model in multi-site studies without sharing individual-level data. Statistical Methods in Medical Research, 2020, 29, 1668-1681.	1.5	30
61	Risk of Psychiatric Adverse Events Among Montelukast Users. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 385-393.e12.	3.8	30
62	Validation of algorithms to ascertain clinical conditions and medical procedures used during pregnancy. Pharmacoepidemiology and Drug Safety, 2011, 20, 1168-1176.	1.9	29
63	Analyzing partially missing confounder information in comparative effectiveness and safety research of therapeutics. Pharmacoepidemiology and Drug Safety, 2012, 21, 13-20.	1.9	28
64	Privacy-preserving Analytic Methods for Multisite Comparative Effectiveness and Patient-centered Outcomes Research. Medical Care, 2014, 52, 664-668.	2.4	28
65	Comparative Effectiveness of Laparoscopic Adjustable Gastric Banding vs Laparoscopic Gastric Bypass. JAMA Surgery, 2014, 149, 1279.	4.3	28
66	Trimethoprim-sulfonamide use during the first trimester of pregnancy and the risk of congenital anomalies. Pharmacoepidemiology and Drug Safety, 2016, 25, 170-178.	1.9	27
67	A <scp>COVID</scp> â€19â€ready public health surveillance system: The Food and Drug Administration's Sentinel System. Pharmacoepidemiology and Drug Safety, 2021, 30, 827-837.	1.9	26
68	Validity of Privacy-Protecting Analytical Methods That Use Only Aggregate-Level Information to Conduct Multivariable-Adjusted Analysis in Distributed Data Networks. American Journal of Epidemiology, 2019, 188, 709-723.	3.4	25
69	Validation of diagnosis codes to identify hospitalized <scp>COVID</scp> â€19 patients in health care claims data. Pharmacoepidemiology and Drug Safety, 2022, 31, 476-480.	1.9	25
70	Broadening the reach of the FDA Sentinel system: A roadmap for integrating electronic health record data in a causal analysis framework. Npj Digital Medicine, 2021, 4, 170.	10.9	25
71	Rapid Assessment of Cardiovascular Risk Among Users of Smoking Cessation Drugs Within the US Food and Drug Administration's Mini-Sentinel Program. JAMA Internal Medicine, 2013, 173, 817.	5.1	24
72	Maternal antibiotic use during pregnancy and childhood obesity at age 5 years. International Journal of Obesity, 2019, 43, 1202-1209.	3.4	23

#	Article	IF	CITATIONS
73	Variance estimation in inverse probability weighted Cox models. Biometrics, 2021, 77, 1101-1117.	1.4	23
74	Prevalence, Trends, and Patterns of Use of Antidiabetic Medications Among Pregnant Women, 2001-2007. Obstetrics and Gynecology, 2013, 121, 106-114.	2.4	22
75	Design and analysis choices for safety surveillance evaluations need to be tuned to the specifics of the hypothesized drug-outcome association. Pharmacoepidemiology and Drug Safety, 2016, 25, 973-981.	1.9	22
76	Validation of claimsâ€based algorithms for identification of highâ€grade cervical dysplasia and cervical cancer. Pharmacoepidemiology and Drug Safety, 2013, 22, 1239-1244.	1.9	21
77	Methods of linking mothers and infants using health plan data for studies of pregnancy outcomes. Pharmacoepidemiology and Drug Safety, 2013, 22, 776-782.	1.9	21
78	Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study. Diabetes Care, 2018, 41, 39-48.	8.6	21
79	Trends in Elective Labor Induction for Six United States Health Plans, 2001–2007. Journal of Women's Health, 2014, 23, 904-911.	3.3	20
80	A proposed approach to accelerate evidence generation for genomic-based technologies in the context of a learning health system. Genetics in Medicine, 2018, 20, 390-396.	2.4	20
81	Validation of the Combined Comorbidity Index of Charlson and Elixhauser to Predict 30-Day Mortality Across ICD-9 and ICD-10. Medical Care, 2018, 56, 812-812.	2.4	19
82	Trends in Dispensing of Zolpidem and Low-Dose Trazodone Among Commercially Insured Adults in the United States, 2011-2018. JAMA - Journal of the American Medical Association, 2020, 324, 2211.	7.4	19
83	Datapoints: Trends in ADHD and Stimulant Use Among Children, 1993-2003. Psychiatric Services, 2006, 57, 1091-1091.	2.0	18
84	Enrollment and Retention in 34 United States Pregnancy Registries Contrasted with the Manufacturer's Capture of Spontaneous Reports for Exposed Pregnancies. Drug Safety, 2018, 41, 87-94.	3.2	18
85	Changing patterns of asthma medication use related to US Food and Drug Administration long-acting β2-agonist regulation from 2005-2011. Journal of Allergy and Clinical Immunology, 2016, 137, 710-717.	2.9	17
86	Accuracy of Electronic Health Record–Derived Data for the Identification of Incident ADHD. Journal of Attention Disorders, 2017, 21, 416-425.	2.6	17
87	Estimating Effects of Dynamic Treatment Strategies in Pharmacoepidemiologic Studies with Time-Varying Confounding: a Primer. Current Epidemiology Reports, 2017, 4, 288-297.	2.4	17
88	Evaluating automated approaches to anaphylaxis case classification using unstructured data from the FDA Sentinel System. Pharmacoepidemiology and Drug Safety, 2018, 27, 1077-1084.	1.9	17
89	The Certainty Framework for Assessing Realâ€World Data in Studies of Medical Product Safety and Effectiveness. Clinical Pharmacology and Therapeutics, 2021, 109, 1189-1196.	4.7	17
90	Risk of Nonmelanoma Skin Cancer in Association With Use of Hydrochlorothiazide-Containing Products in the United States. JNCI Cancer Spectrum, 2021, 5, pkab009.	2.9	17

#	Article	IF	CITATIONS
91	Development and Application of Two Semi-Automated Tools for Targeted Medical Product Surveillance in a Distributed Data Network. Current Epidemiology Reports, 2017, 4, 298-306.	2.4	16
92	Prospective surveillance pilot of rivaroxaban safety within the US Food and Drug Administration Sentinel System. Pharmacoepidemiology and Drug Safety, 2018, 27, 263-271.	1.9	16
93	A Query Workflow Design to Perform Automatable Distributed Regression Analysis in Large Distributed Data Networks. EGEMS (Washington, DC), 2018, 6, 11.	2.0	16
94	Use of tumor necrosis factorâ€alpha inhibitors during pregnancy among women who delivered live born infants. Pharmacoepidemiology and Drug Safety, 2019, 28, 296-304.	1.9	15
95	Electronic phenotyping of health outcomes of interest using a linked claims-electronic health record database: Findings from a machine learning pilot project. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 1507-1517.	4.4	15
96	Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018. JAMA Internal Medicine, 2021, 181, 1596-1604.	5.1	14
97	An Analytic Framework for Aligning Observational and Randomized Trial Data: Application to Postmenopausal Hormone Therapy and Coronary Heart Disease. Statistics in Biosciences, 2013, 5, 344-360.	1.2	13
98	Comparison of privacyâ€protecting analytic and dataâ€sharing methods: A simulation study. Pharmacoepidemiology and Drug Safety, 2018, 27, 1034-1041.	1.9	13
99	Combining distributed regression and propensity scores: a doubly privacy-protecting analytic method for multicenter research. Clinical Epidemiology, 2018, Volume 10, 1773-1786.	3.0	13
100	Analytic and Data Sharing Options in Realâ€World Multidatabase Studies of Comparative Effectiveness and Safety of Medical Products. Clinical Pharmacology and Therapeutics, 2020, 107, 834-842.	4.7	13
101	Association of Early Antibiotic Exposure With Childhood Body Mass Index Trajectory Milestones. JAMA Network Open, 2021, 4, e2116581.	5.9	13
102	Diagnostic Algorithms for Cardiovascular Death in Administrative Claims Databases: A Systematic Review. Drug Safety, 2019, 42, 515-527.	3.2	12
103	Effect of <scp>ICDâ€9â€CM</scp> to <scp>ICDâ€10â€CM</scp> coding system transition on identification of common conditions: An interrupted time series analysis. Pharmacoepidemiology and Drug Safety, 2021, 30, 1653-1674.	1.9	12
104	Reâ€using Mini‣entinel data following rapid assessments of potential safety signals via modular analytic programs. Pharmacoepidemiology and Drug Safety, 2013, 22, 1036-1045.	1.9	11
105	Big Data in Epidemiology. Epidemiology, 2013, 24, 939.	2.7	11
106	Utilization of drugs with pregnancy exposure registries during pregnancy. Pharmacoepidemiology and Drug Safety, 2018, 27, 604-611.	1.9	11
107	Safe Expectations: Current State and Future Directions for Medication Safety in Pregnancy Research. Clinical Therapeutics, 2019, 41, 2467-2476.	2.5	11
108	Building an active medical product safety surveillance system in Taiwan: Adaptation of the U.S. Sentinel System common data model structure to the National Health Insurance Research Database in Taiwan. Pharmacoepidemiology and Drug Safety, 2021, 30, 97-101.	1.9	11

#	Article	IF	CITATIONS
109	Pharmacotherapy for incident attention-deficit/hyperactivity disorder: practice patterns and quality metrics. Current Medical Research and Opinion, 2014, 30, 1687-1699.	1.9	10
110	Safety assessment of niacin in the US Food and Drug Administration's miniâ€sentinel system. Pharmacoepidemiology and Drug Safety, 2018, 27, 30-37.	1.9	10
111	Association of Risk for Venous Thromboembolism With Use of Low-Dose Extended- and Continuous-Cycle Combined Oral Contraceptives. JAMA Internal Medicine, 2018, 178, 1482.	5.1	10
112	Misclassification in Assessment of First Trimester In-utero Exposure to Drugs Used Proximally to Conception: the Example of Letrozole Utilization for Infertility Treatment. American Journal of Epidemiology, 2019, 188, 418-425.	3.4	10
113	Privacy-protecting multivariable-adjusted distributed regression analysis for multi-center pediatric study. Pediatric Research, 2020, 87, 1086-1092.	2.3	10
114	National Trends in Prescribing Antidepressants Before and After an FDA Advisory on Suicidality Risk in Youths. Psychiatric Services, 2011, 62, 727-733.	2.0	9
115	Comparative cardiovascular safety of nonsteroidal antiâ€inflammatory drugs in patients with hypertension: a populationâ€based cohort study. British Journal of Clinical Pharmacology, 2018, 84, 1045-1056.	2.4	9
116	Near Real-time Surveillance for Consequences of Health Policies Using Sequential Analysis. Medical Care, 2018, 56, 365-372.	2.4	9
117	Use of Time-Dependent Propensity Scores to Adjust Hazard Ratio Estimates in Cohort Studies with Differential Depletion of Susceptibles. Epidemiology, 2020, 31, 82-89.	2.7	9
118	Understanding utilization patterns of biologics and biosimilars in the United States to support postmarketing studies of safety and effectiveness. Pharmacoepidemiology and Drug Safety, 2020, 29, 786-795.	1.9	9
119	Translating claimsâ€based CHA ₂ DS ₂ â€VaSc and HASâ€BLED to ICDâ€10â€CM: Impact mapping strategies. Pharmacoepidemiology and Drug Safety, 2020, 29, 409-418.	s of 1.9	9
120	Comparing Prescribing and Dispensing Data of the PCORnet Common Data Model Within PCORnet Antibiotics and Childhood Growth Study. EGEMS (Washington, DC), 2019, 7, 11.	2.0	9
121	Comparative cardiovascular effectiveness of glucagonâ€like peptideâ€1 receptor agonists versus sodiumâ€glucose cotransporterâ€2 inhibitors in patients with type 2 diabetes: A populationâ€based cohort study. Diabetes, Obesity and Metabolism, 2022, 24, 1623-1637.	4.4	9
122	The Prevalence and Trends of Antiviral Medication Use During Pregnancy in the US: A Population-Based Study of 664,297 Deliveries in 2001–2007. Maternal and Child Health Journal, 2014, 18, 64-72.	1.5	8
123	Outpatient influenza antivirals in a distributed data network for influenza surveillance. Influenza and Other Respiratory Viruses, 2018, 12, 804-807.	3.4	8
124	Extension of Disease Risk Score–Based Confounding Adjustments for Multiple Outcomes of Interest: An Empirical Evaluation. American Journal of Epidemiology, 2018, 187, 2439-2448.	3.4	8
125	Leveraging the Capabilities of the FDA's Sentinel System To Improve Kidney Care. Journal of the American Society of Nephrology: JASN, 2020, 31, 2506-2516.	6.1	8
126	Early Life Antibiotic Prescriptions and Weight Outcomes in Children 10 Years of Age. Academic Pediatrics, 2021, 21, 297-303.	2.0	8

#	Article	IF	CITATIONS
127	Antipsychotic Use and Stroke. Journal of Clinical Psychiatry, 2019, 80, .	2.2	8
128	Frequency estimates from prescription drug datasets (revision of #04-11-066A). Pharmacoepidemiology and Drug Safety, 2006, 15, 512-520.	1.9	7
129	Sequential surveillance for drug safety in a regulatory environment. Pharmacoepidemiology and Drug Safety, 2018, 27, 707-712.	1.9	7
130	Incidence of Heart Failure and Cardiomyopathy Following Initiation of Medications for Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology, 2018, 38, 505-508.	1.4	7
131	Uptake of new drugs in the early post-approval period in the Mini-Sentinel distributed database. Pharmacoepidemiology and Drug Safety, 2016, 25, 1023-1032.	1.9	6
132	Pharmacoepidemiology in the Era of Real-World Evidence. Current Epidemiology Reports, 2017, 4, 262-265.	2.4	6
133	Evaluation of the US Food and Drug Administration sentinel analysis tools in confirming previously observed drugâ€outcome associations: The case of clindamycin and <i>Clostridium difficile</i> infection. Pharmacoepidemiology and Drug Safety, 2018, 27, 731-739.	1.9	6
134	Assessing the impact of the new ICDâ€10â€CM coding system on pharmacoepidemiologic studies—An application to the known association between angiotensinâ€converting enzyme inhibitors and angioedema. Pharmacoepidemiology and Drug Safety, 2018, 27, 829-838.	1.9	6
135	Use of Antidiabetic drugs during pregnancy among U.S. women with Livebirth deliveries in the Mini-Sentinel system. BMC Pregnancy and Childbirth, 2019, 19, 441.	2.4	6
136	Consequences of Depletion of Susceptibles for Hazard Ratio Estimators Based on Propensity Scores. Epidemiology, 2020, 31, 806-814.	2.7	6
137	Statin use is associated with lower risk of dementia in stroke patients: a community-based cohort study with inverse probability weighted marginal structural model analysis. European Journal of Epidemiology, 2022, 37, 615-627.	5.7	6
138	The Devil's in the details: Reports on reproducibility in pharmacoepidemiologic studies. Pharmacoepidemiology and Drug Safety, 2019, 28, 671-679.	1.9	5
139	Suitability of administrative claims databases for bariatric surgery research – is the glass half-full or half-empty?. BMC Medical Research Methodology, 2020, 20, 225.	3.1	5
140	Estimating the marginal hazard ratio by simultaneously using a set of propensity score models: A multiply robust approach. Statistics in Medicine, 2021, 40, 1224-1242.	1.6	5
141	Datapoints: Trends in ADHD and Stimulant Use Among Children, 1993-2003. Psychiatric Services, 2006, 57, 1091-1091.	2.0	5
142	Distributed Regression Analysis Application in Large Distributed Data Networks: Analysis of Precision and Operational Performance. JMIR Medical Informatics, 2020, 8, e15073.	2.6	5
143	Use of Linked Databases for Improved Confounding Control: Considerations for Potential Selection Bias. American Journal of Epidemiology, 2022, , .	3.4	5
144	Applying Machine Learning in Distributed Data Networks for Pharmacoepidemiologic and Pharmacovigilance Studies: Opportunities, Challenges, and Considerations. Drug Safety, 2022, 45, 493-510.	3.2	5

#	Article	IF	CITATIONS
145	Characteristics of study design and elements that may contribute to the success of electronic safety monitoring systems. Pharmacoepidemiology and Drug Safety, 2014, 23, 1223-1225.	1.9	4
146	National Trends in Outpatient Antihypertensive Prescribing in People withÂDementia in the United States. Journal of Alzheimer's Disease, 2016, 54, 1425-1435.	2.6	4
147	Evaluation of the US Food and Drug Administration Sentinel Analysis Tools Using a Comparator with a Different Indication: Comparing the Rates of Gastrointestinal Bleeding in Warfarin and Statin Users. Pharmaceutical Medicine, 2019, 33, 29-43.	1.9	4
148	Evaluating the use of bootstrapping in cohort studies conducted with 1:1 propensity score matching—A plasmode simulation study. Pharmacoepidemiology and Drug Safety, 2019, 28, 879-886.	1.9	4
149	Privacy-protecting estimation of adjusted risk ratios using modified Poisson regression in multi-center studies. BMC Medical Research Methodology, 2019, 19, 228.	3.1	4
150	Distributed Cox proportional hazards regression using summary-level information. Biostatistics, 2023, 24, 776-794.	1.5	4
151	Lower Cancer Incidence—Warfarin Effect or Immortal Time Bias?. JAMA Internal Medicine, 2018, 178, 584.	5.1	3
152	Reproducing Protocolâ€Based Studies Using Parameterizable Tools—Comparison of Analytic Approaches Used by Two Medical Product Surveillance Networks. Clinical Pharmacology and Therapeutics, 2020, 107, 966-977.	4.7	3
153	Overall and causeâ€specific mortality in the Sentinel system: A power analysis. Pharmacoepidemiology and Drug Safety, 2018, 27, 1416-1421.	1.9	2
154	Prevalence of prescription opioid use during pregnancy in eight US health plans during 2001–2014. Pharmacoepidemiology and Drug Safety, 2021, 30, 1541-1550.	1.9	2
155	Who gets treated for influenza: A surveillance study from the US Food and Drug Administration's Sentinel System. Infection Control and Hospital Epidemiology, 2022, 43, 1228-1234.	1.8	2
156	Controlling Confounding in a Study of Oral Anticoagulants: Comparing Disease Risk Scores Developed Using Different Follow-Up Approaches. EGEMS (Washington, DC), 2019, 7, 27.	2.0	2
157	Developing a Standardized and Reusable Method to Link Distributed Health Plan Databases to the National Death Index: Methods Development Study Protocol. JMIR Research Protocols, 2020, 9, e21811.	1.0	2
158	Evaluating Confounding Control in Estimations of Influenza Antiviral Effectiveness in Electronic Health Plan Data. American Journal of Epidemiology, 2022, 191, 908-920.	3.4	2
159	Continuity and Completeness of Electronic Health Record Data for Patients Treated With Oral Hypoglycemic Agents: Findings From Healthcare Delivery Systems in Taiwan. Frontiers in Pharmacology, 2022, 13, 845949.	3.5	2
160	Toh et al. Respond to "Compromise or Compromising?". American Journal of Epidemiology, 2007, 167, 644-645.	3.4	1
161	The impact of FDA regulatory activities on incident dispensing of LABA-containing medication: 2005–2011. Journal of Asthma, 2018, 55, 907-914.	1.7	1
162	Sound-Alike Look-Alike Confusion and Matching Medication Product Attributes: Simulated Case-Control Studies. Annals of Pharmacotherapy, 2019, 53, 973-980.	1.9	1

#	Article	IF	CITATIONS
163	Automatable Distributed Regression Analysis of Vertically Partitioned Data Facilitated by PopMedNet: Feasibility and Enhancement Study. JMIR Medical Informatics, 2021, 9, e21459.	2.6	1
164	Translating stakeholder-driven comparative effectiveness research into practice: the PCORnet Bariatric Study. Journal of Comparative Effectiveness Research, 2020, 9, 1035-1041.	1.4	1
165	Utility of fertility procedures and prenatal tests to estimate gestational age for liveâ€births and stillbirths in electronic health plan databases. Pharmacoepidemiology and Drug Safety, 2022, , .	1.9	1
166	Profiling realâ€world data sources for pharmacoepidemiologic research: A call for papers. Pharmacoepidemiology and Drug Safety, 2022, 31, 929-931.	1.9	1
167	Go BIG and Go Global: Executing Large-Scale, Multi-Site Pharmacoepidemiologic Studies Using Real-world Data. American Journal of Epidemiology, 0, , .	3.4	1
168	MH1 NATIONAL TRENDS IN THE DIAGNOSIS OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDERAND USE OF STIMULANTS AMONG CHILDREN IN THE UNITED STATES, 1993-2003. Value in Health, 2006, 9, A15.	0.3	0
169	PMH16 HEALTH CARE COSTS AND UTILIZATION PATTERNS OF INDIVIDUALS WITH GENERALIZED ANXIETY DISORDER (GAD) IN THE UNITED STATES. Value in Health, 2006, 9, A69.	0.3	0
170	PMH87 NATIONAL TRENDS IN PRESCRIBING ANTIDEPRESSANTS FOR DEPRESSION—BEFORE AND AFTER FDA ADVISORY ON RISK OF SUICIDALITY AMONG CHILDREN AND ADOLESCENTS. Value in Health, 2010, 13, A121.	0.3	0
171	Letter in response to Schneeweiss and Rassen on the high-dimensional propensity score approach. Pharmacoepidemiology and Drug Safety, 2011, 20, 1112-1112.	1.9	0
172	PCV12 Determinants of Exposure to Potential Interactions Between Antiplatelet Drugs, Anticoagulants, Digoxin and Common Chinese Medications in Taiwan. Value in Health, 2012, 15, A631.	0.3	0
173	Response to the letter by Mol. Pharmacoepidemiology and Drug Safety, 2014, 23, 106-106.	1.9	0
174	RE: Drug risk assessment and data reuse. Pharmacoepidemiology and Drug Safety, 2014, 23, 109-110.	1.9	0
175	4.16 HEART FAILURE AND CARDIOMYOPATHY FOLLOWING INITIATION OF MEDICATIONS FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, S168.	0.5	0
176	Network Meta-Analysis Using Observational Data From Distributed Health Data Networks: A Conceptual Framwork And Illustrative Example. Value in Health, 2016, 19, A108.	0.3	0
177	Identification of potential drug name confusion errors in the Sentinel System. Pharmacoepidemiology and Drug Safety, 2019, 28, 1405-1410.	1.9	0
178	Use of Intrauterine Devices and Risk of Human Immunodeficiency Virus Acquisition Among Insured Women in the United States. Clinical Infectious Diseases, 2020, 70, 2221-2223.	5.8	0
179	Validity of diagnosis and procedure codes for identifying neural tube defects in infants. Pharmacoepidemiology and Drug Safety, 2020, 29, 1489-1493.	1.9	0
180	Conducting prospective sequential surveillance in realâ€world dynamic distributed databases. Pharmacoepidemiology and Drug Safety, 2020, 29, 1331-1335.	1.9	0

#	Article	IF	CITATIONS
181	Menopausal Hormone Therapy and Risk for Cardiovascular Disease in the WHI Trial. Annals of Internal Medicine, 2010, 153, 61.	3.9	0
182	Sulfonamide Use During the First Trimester of Pregnancy and Risk of Selected Congenital Anomalies Among Live Births. Journal of Patient-centered Research and Reviews, 2016, 3, 202-203.	0.9	0
183	Concomitant Filled Prescriptions of Oxymorphone or Oxycodone with CYP3A Inhibitors and Inducers. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 668-672.	0.9	0
184	ppmHR. Epidemiology, 2021, 32, e6-e7.	2.7	0
185	Antibiotics prior to age 2 years have limited association with preschool growth trajectory. International Journal of Obesity, 2022, 46, 843-850.	3.4	0